Shares of InMed Pharmaceuticals Inc. (INM) are up over 70% at $4.18 today, following new preclinical data of INM-901 in Alzheimer's disease.
In ex vivo models of Lipopolysaccharide (LPS)-induced inflammation in animal brain tissue, INM-901 demonstrated statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1ß, IL-2, and KC/Gro. It also significantly reduced levels of the inflammasome marker, NLRP3.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.